Cancer arises from somatic mutations accumulating within a cell, disrupting crucial cellular processes like growth regulation and apoptosis.  Recent advancements in understanding the genetic basis of cancer have revolutionized personalized medicine.  Next-generation sequencing (NGS) technologies now allow for comprehensive profiling of tumor genomes, identifying driver mutations specific to an individual's cancer. This enables the precise classification of cancer subtypes beyond traditional histological approaches, revealing targetable vulnerabilities for therapy.  

Developments in CRISPR-Cas9 gene editing offer the potential for precise correction of driver mutations or disruption of oncogenes, although challenges remain regarding delivery and off-target effects.  Immuno-oncology has also been significantly advanced, leveraging knowledge of tumor neoantigens identified through genomic profiling to design personalized cancer vaccines or enhance checkpoint inhibitor efficacy.  Liquid biopsies, using circulating tumor DNA (ctDNA), provide a minimally invasive method for monitoring disease progression and treatment response, allowing for timely adjustments to therapeutic strategies.  While significant challenges persist regarding drug resistance and the complexity of tumor heterogeneity, the integration of genomic data with clinical information promises increasingly effective and personalized cancer treatments.